Genetron Health Announces Changes to the Board of Directors and Executive Officer
Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced changes to the Company’s Board of Directors (the “Board”) and executive team.
Dr. Chao Tang and Mr. Shan Fu have been appointed as Directors of the Company, effective immediately. Dr. Chao Tang will replace Dr. Weiwu He, who has served as Chairman of the Board since May 2015. Mr. Shan Fu will replace Mr. Weidong Liu, who has served as Director since November 2019. Both Dr. He and Mr. Liu resigned from the Board due to personal reasons. In recognition of Dr. He’s invaluable contributions to the Company during his tenure of services, the Board has appointed him as Chairman Emeritus of the Board. The Board has also appointed Mr. Sizhen Wang as the new Chairman of the Board.
“It is my pleasure to welcome Dr. Tang and Mr. Fu to the Board,” commented Mr. Sizhen Wang, co-founder, Chairman and CEO of Genetron Health. “Dr. Tang’s expertise and academic achievements in interdisciplinary sciences across physics and biology, and Mr. Fu’s corporate board experience and expertise in the global healthcare industry will strengthen Genetron. I look forward to working with them closely in achieving our mission to transform cancer treatment and prevention globally.”
Dr. He commented, “It is my great honor to have founded Genetron Health with two outstanding partners, Mr. Sizhen Wang and Dr. Hai Yan. We have taken the Company from a start-up to one of the leading precision oncology companies in China. As Genetron Health enters its next phase of growth, I believe that adding both Dr. Tang and Mr. Fu to the Board are excellent choices given their outstanding backgrounds and significant achievements. I am very thankful for the opportunity to be a part of this Company’s exciting journey, and I am confident that Genetron Health is poised for significant growth in the future.”
In addition, effective June 30th, 2021, Mr. Kevin Ying Hong will become a Senior Advisor to Genetron Health. Mr. Hong has been a significant contributor to the growth and success of Genetron Health and his expertise can continue to help the company, following his resignation as COO from the company for personal reasons.
Mr. Wang said, “We would like to thank Dr. He, Mr. Liu and Mr. Hong for their contributions to the Company’s success. We are grateful for Dr. He’s visionary leadership since the inception of Genetron Health, and his support for the Company’s strategic goals. We also very much appreciate Mr. Liu for his guidance and service to the Board. Finally, we would like to thank Mr. Hong for his tremendous work in building the foundation for our business operations to support the Company’s rapid growth.”
Dr. Chao Tang is a Chair Professor of Physics and Systems Biology and the Executive Dean of the Academy for Advanced Interdisciplinary Studies at Peking University. In his early career, Dr. Tang worked on pioneering research in the fields of statistical physics, condensed matter physics, dynamical and complex systems while in the United States. His current research interest is at the interface between physics and biology, in particular systems biology and biological physics. Dr. Tang was a tenured full professor at the University of California San Francisco before returning to China full-time in 2011. He is a Fellow of the American Physical Society, an Academician of the Chinese Academy of Sciences, the founding director of the Center for Quantitative Biology at Peking University and the founding Co-Editor-in-Chief of the journal Quantitative Biology. Dr. Tang had his undergraduate training at the University of Science and Technology of China and received a Ph.D. degree in Physics from the University of Chicago. He has also conducted extensive postdoctoral training at the Brookhaven National Laboratory and the Kavli Institute for Theoretical Physics of the University of California, Santa Barbara.
